Vir Biotechnology (NASDAQ:VIR) Director Sells $30,240.00 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) Director Janet Napolitano sold 3,200 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $9.45, for a total value of $30,240.00. Following the sale, the director directly owned 21,216 shares of the company’s stock, valued at $200,491.20. The trade was a 13.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vir Biotechnology Trading Down 3.2%

Shares of Vir Biotechnology stock traded down $0.29 on Tuesday, reaching $8.74. 1,411,160 shares of the stock were exchanged, compared to its average volume of 2,800,216. The business has a fifty day moving average price of $9.49 and a two-hundred day moving average price of $7.96. Vir Biotechnology, Inc. has a 1-year low of $4.16 and a 1-year high of $11.66. The firm has a market capitalization of $1.47 billion, a PE ratio of -2.79 and a beta of 1.65.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.84). The business had revenue of ($0.03) million during the quarter, compared to analyst estimates of $55.49 million. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 53.31%. During the same period in the prior year, the business earned ($0.88) earnings per share. Research analysts expect that Vir Biotechnology, Inc. will post -1.75 EPS for the current year.

Hedge Funds Weigh In On Vir Biotechnology

A number of institutional investors have recently made changes to their positions in VIR. Raymond James Financial Inc. acquired a new position in shares of Vir Biotechnology in the second quarter worth $35,000. FNY Investment Advisers LLC acquired a new position in shares of Vir Biotechnology in the third quarter worth $38,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Vir Biotechnology by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company’s stock worth $41,000 after acquiring an additional 1,390 shares during the last quarter. UMB Bank n.a. raised its holdings in shares of Vir Biotechnology by 1,418.7% in the fourth quarter. UMB Bank n.a. now owns 7,062 shares of the company’s stock worth $43,000 after acquiring an additional 6,597 shares during the last quarter. Finally, Federated Hermes Inc. raised its holdings in shares of Vir Biotechnology by 153.8% in the third quarter. Federated Hermes Inc. now owns 8,085 shares of the company’s stock worth $46,000 after acquiring an additional 4,899 shares during the last quarter. 65.32% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Evercore reissued an “outperform” rating and issued a $18.00 price target on shares of Vir Biotechnology in a report on Tuesday, February 24th. Wall Street Zen cut Vir Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. HC Wainwright boosted their target price on Vir Biotechnology from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Barclays raised their target price on shares of Vir Biotechnology from $26.00 to $30.00 and gave the company an “overweight” rating in a report on Tuesday, February 24th. Finally, Morgan Stanley set a $23.00 target price on shares of Vir Biotechnology in a research report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $20.25.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.